Alyson Haslam
Research Data Analyst
Epidemiology & Biostatistics
School of Medicine

Publications (96)

Top publication keywords:
Cross-Sectional StudiesDrug ApprovalMedical OncologyPsychological TestsPeriodicals as TopicPublicationsPharmaceutical PreparationsPhysiciansRandomized Controlled Trials as TopicResearch DesignAntineoplastic Agents, ImmunologicalNeoplasmsUnited States Food and Drug AdministrationConflict of InterestAntineoplastic Agents

• INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas.
  Journal of cancer policy 2024 Zugman M, Haslam A, Prasad V
• Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis.
  European journal of cancer (Oxford, England : 1990) 2024 Lam M, Olivier T, Haslam A, Tuia J, Prasad V
• Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review.
  Targeted oncology 2024 Crotty P, Kari K, Hughes GK, Ladd C, McIntire R, Gardner B, Peña AM, Ferrell S, Tuia J, Cohn J, Haslam A, Prasad V, Vassar M
• COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementation.
  Monash bioethics review 2024 Prasad V, Haslam A
• Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
  Cancer medicine 2024 Benjamin DJ, Haslam A, Prasad V

Show all (91 more) Hide

• Justification for unequal allocation ratios in clinical trials: A scoping review.
  Contemporary clinical trials 2024 Nay J, Haslam A, Prasad V
• Estimation of eligibility for and response to CAR-T therapy in the United States.
  Blood advances 2024 Haslam A, Hoeg TB, Prasad V
• Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops.
  European journal of clinical investigation 2024 Miller SL, Haslam A, Prasad V
• The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds.
  Epidemiology and infection 2024 Høeg TB, Haslam A, Prasad V
• Discrepancies in Estimating Excess Death by Political Party Affiliation During the COVID-19 Pandemic.
  JAMA internal medicine 2024 Dasaro C, Haslam A, Prasad V
• Assessing patient burden and benefit: A decade of cabozantinib clinical trials.
  International journal of cancer 2023 Hughes GK, Sajjadi NB, Gardner B, Ramoin JK, Tuia J, Haslam A, Prasad V, Vassar M
• Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy.
  Journal of cancer policy 2023 Ranganathan S, Haslam A, Tuia J, Prasad V
• Cancer Drug Price and Novelty in Mechanism of Action.
  JAMA network open 2023 Miljkovic MD, Tuia J, Olivier T, Haslam A, Prasad V
• Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout.
  The American journal of medicine 2023 Haslam A, Tuia J, Miller SL, Prasad V
• Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.
  JAMA network open 2023 Olivier T, Haslam A, Tuia J, Prasad V
• An Analysis of Studies Pertaining to Masks in Morbidity and Mortality Weekly Report: Characteristics and Quality of Studies through 2023.
  The American journal of medicine 2023 Høeg TB, Haslam A, Prasad V
• Flu advice in the U.S. news media changed during the COVID-19 pandemic but not the evidence.
  European journal of epidemiology 2023 Brown E, Haslam A, Prasad V
• Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer.
  BMC medicine 2023 Olivier T, Haslam A, Prasad V
• Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs.
  JAMA oncology 2023 Lam M, Olivier T, Haslam A, Tuia J, Prasad V
• Evidence Base for Health Care Strategies to Protect Vulnerable Patients During the COVID-19 Pandemic.
  JAMA oncology 2023 Haslam A, Prasad V
• Multiple myeloma: challenges with deciding the optimal sequencing strategy.
  Frontiers in pharmacology 2023 Walia A, Haslam A, Tuia J, Prasad V
• Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use.
  Trials 2023 Prasad V, Kim MS, Haslam A
• Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022.
  Journal of cancer policy 2023 Olivier T, Smith CEP, Haslam A, Addeo A, Prasad V
• Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals.
  JAMA network open 2023 Haslam A, Tuia J, Prasad V
• Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020.
  BMC cancer 2023 Olivier T, Haslam A, Prasad V
• Profile of the Oncology Physician Workforce and the Characteristics of Attrition.
  JCO oncology practice 2023 Tuia J, Haslam A, Prasad V
• Cross-sectional analysis of open payments for physicians at designated hemophilia centers in the US (2018-2020).
  Thrombosis research 2023 Haslam A, Prasad V
• Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis.
  JAMA internal medicine 2023 Banerjee T, Kim MS, Haslam A, Prasad V
• Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials?
  Journal of cancer policy 2023 Olivier T, Haslam A, Prasad V
• The definition of long COVID used in interventional studies.
  European journal of clinical investigation 2023 Haslam A, Olivier T, Prasad V
• Omission of Critical Information From Clinical Trial Reports-What to Do About Uninterpretable Results.
  JAMA oncology 2023 Olivier T, Haslam A, Prasad V
• The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review.
  Journal of cancer research and clinical oncology 2023 Bhatt A, Haslam A, Prasad V
• The response rate by tumour type for tissue-agnostic approved drugs.
  European journal of cancer (Oxford, England : 1990) 2023 Haslam A, Prasad V
• Design, power, and alpha levels in randomized phase II oncology trials.
  ESMO open 2023 Haslam A, Olivier T, Prasad V
• Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals.
  JAMA network open 2023 Buck E, Haslam A, Tuia J, Prasad V
• Comparability of Control and Comparison Groups in Studies Assessing Long COVID.
  The American journal of medicine 2023 Haslam A, Prasad V
• Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers.
  BMC cancer 2023 Haslam A, Olivier T, Tuia J, Prasad V
• Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
  Translational oncology 2022 Olivier T, Haslam A, Prasad V
• Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
  British journal of haematology 2022 Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR
• Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.
  JAMA internal medicine 2022 Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V
• Financial conflicts of interest of OncoAlert: An informal oncology professional network.
  Journal of cancer policy 2022 Powell K, Kakkilaya A, Haslam A, Prasad V
• A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target.
  European journal of cancer (Oxford, England : 1990) 2022 Haslam A, Olivier T, Tuia J, Prasad V
• Brentuximab Vedotin in Advanced Hodgkin's Lymphoma.
  The New England journal of medicine 2022 Haslam A, Prasad V
• What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).
  BMJ open 2022 Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V
• Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis.
  Journal of cancer policy 2022 Prasad V, Olivier T, Chen EY, Haslam A
• FDA validation of surrogate endpoints in oncology: 2005-2022.
  Journal of cancer policy 2022 Walia A, Haslam A, Prasad V
• Characteristics of Facebook's third-party medical fact checkers.
  Digital health 2022 Haslam A, Prasad V
• Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021.
  European journal of cancer (Oxford, England : 1990) 2022 Olivier T, Haslam A, Prasad V
• Eventual success rate and predictors of success for oncology drugs tested in phase I trials.
  International journal of cancer 2022 Haslam A, Olivier T, Powell K, Tuia J, Prasad V
• Impact of a Farm-to-School Nutrition and Gardening Intervention for Native American Families from the FRESH Study: A Randomized Wait-List Controlled Trial.
  Nutrients 2022 Taniguchi T, Haslam A, Sun W, Sisk M, Hayman J, Jernigan VBB
• Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials.
  JAMA network open 2022 Ahmed N, Vengalasetti Y, Haslam A, Prasad V
• Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?
  ESMO open 2022 Haslam A, Olivier T, Thawani R, Prasad V
• Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident.
  European journal of emergency medicine : official journal of the European Society for Emergency Medicine 2022 Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V
• Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
  Cancer medicine 2022 Benjamin DJ, Haslam A, Gill J, Prasad V
• Characteristics of oncology podcasts: Attitudes, speakers, conflicts.
  Journal of cancer policy 2022 Akman EG, Powell K, Haslam A, Prasad V
• Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
  International journal of cancer 2022 Kim MS, Xu A, Haslam A, Prasad V
• Design and Methods of a Participatory Healthy Eating Intervention for Indigenous Children: The FRESH Study.
  Frontiers in public health 2022 Blue Bird Jernigan V, Taniguchi T, Haslam A, Williams MB, Maudrie TL, Nikolaus CJ, Wetherill MS, Jacob T, Love CV, Sisson S
• Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.
  European journal of cancer (Oxford, England : 1990) 2022 Maniar A, Haslam A, Prasad V
• The effect of food prescription programs on chronic disease management in primarily low-income populations: A systematic review and meta-analysis.
  Nutrition and health 2022 Haslam A, Gill J, Taniguchi T, Love C, Jernigan VB
• Development and Implementation of a Hybrid Online and In-Person Food Sovereignty and Nutrition Education Curriculum for Native American Parents: The FRESH Study.
  Health education & behavior : the official publication of the Society for Public Health Education 2022 Haslam A, Love C, Taniguchi T, Williams MB, Wetherill MS, Sisson S, Weedn AE, Jacob T, Blue Bird Jernigan V
• Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials.
  JAMA network open 2022 Olivier T, Haslam A, Prasad V
• Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature.
  JAMA internal medicine 2022 Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V
• How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature.
  Inquiry : a journal of medical care organization, provision and financing 2022 Haslam A, Powell K, Prasad V
• A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers.
  Journal of cancer policy 2021 Prasad V, Haslam A, Tuia J
• Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
  JAMA network open 2021 Olivier T, Haslam A, Prasad V
• Artificial intelligence and magnetic resonance imaging may not make cancer screening better.
  Journal of cancer policy 2021 Powell K, Kim MS, Haslam A, Prasad V
• The frequency of assessment of progression in randomized oncology clinical trials.
  Cancer reports (Hoboken, N.J.) 2021 Haslam A, Gill J, Prasad V
• Overall survival for oncology drugs approved for genomic indications.
  European journal of cancer (Oxford, England : 1990) 2021 Haslam A, Kim MS, Prasad V
• Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.
  JAMA network open 2021 Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V
• An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence Based?
  The American journal of medicine 2021 Powell K, Haslam A, Prasad V
• An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals.
  Digestive diseases and sciences 2021 Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B
• The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018.
  BMC cancer 2021 Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V
• Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials.
  Journal of clinical epidemiology 2021 Olivier T, Haslam A, Prasad V
• Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Haslam A, Kim MS, Prasad V
• Perceived Environments and Physical Activity Among American Indian Adults Living in Oklahoma: The THRIVE Study.
  Progress in community health partnerships : research, education, and action 2021 Haslam A, Taniguchi T, Love C, Jacob T, Cannady TK, Standridge J, Grammar M, Fox J, Spiegel J, Crain T, Jernigan VBB
• Perceived Environments and Physical Activity Among American Indian Adults Living in Oklahoma: The THRIVE Study.
  Progress in community health partnerships : research, education, and action 2021 Haslam A, Taniguchi T, Love C, Jacob T, Cannady TK, Standridge J, Grammar M, Fox J, Spiegel J, Crain T, Jernigan VBB
• The response rate of alternative treatments for drugs approved on the basis of response rate.
  International journal of cancer 2020 Haslam A, Gill J, Prasad V
• FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019.
  JAMA internal medicine 2020 Chen EY, Haslam A, Prasad V
• Estimation of US patients with cancer who may respond to cytotoxic chemotherapy.
  Future science OA 2020 Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V
• Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists.
  JAMA internal medicine 2020 Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V
• Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Hazim A, Mills G, Prasad V, Haslam A, Chen EY
• Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs.
  JAMA network open 2020 Haslam A, Gill J, Prasad V
• Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials.
  JAMA network open 2020 Haslam A, Herrera-Perez D, Gill J, Prasad V
• Medical Reversals in Family Practice: A Review.
  Current therapeutic research, clinical and experimental 2020 Haslam A, Livingston C, Prasad V
• An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Haslam A, Gill J, Prasad V
• Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions.
  Mayo Clinic proceedings 2020 Haslam A, Gill J, Prasad V
• Medical reversals in low- and middle-income countries.
  The International journal of health planning and management 2019 Haslam A, Prasad V, Livingston C
• Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
  JAMA network open 2019 de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V
• A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals.
  eLife 2019 Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu AS, Prasad V
• Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?
  Mayo Clinic proceedings 2019 Chapa J, Haslam A, Prasad V
• Confirmatory Trials for Drugs Approved on a Single Trial.
  Circulation. Cardiovascular quality and outcomes 2019 Haslam A, Prasad V
• Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
  JAMA network open 2019 Haslam A, Prasad V
• Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs.
  The American journal of medicine 2019 Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V
• A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.
  European journal of cancer (Oxford, England : 1990) 2018 Haslam A, Hey SP, Gill J, Prasad V
• Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That?
  Circulation. Cardiovascular quality and outcomes 2018 Haslam A, Prasad V
• Association between dietary pattern scores and the prevalence of colorectal adenoma considering population subgroups.
  Nutrition & dietetics: the journal of the Dietitians Association of Australia 2017 Haslam A, Wagner Robb S, Hébert JR, Huang H, Ebell MH